Management of patients with lower-risk myelodysplastic syndromes.

Brunner, Andrew M; Leitch, Heather A; van de Loosdrecht, Arjan A; Bonadies, Nicolas (2022). Management of patients with lower-risk myelodysplastic syndromes. Blood cancer journal, 12(166), p. 166. Nature Publishing Group 10.1038/s41408-022-00765-8

Preview

Text s41408-022-00765-8.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (770kB) | Preview

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis with abnormal blood cell development (dysplasia) leading to cytopenias and an increased risk for progression to acute myeloid leukemia (AML). Patients with MDS can generally be classified as lower- (LR-MDS) or higher-risk (HR-MDS). As treatment goals for patients with LR-MDS and those with HR-MDS differ significantly, appropriate diagnosis, classification, and follow-up are critical for correct disease management. In this review, we focus on the diagnosis, prognosis, and treatment options, as well as the prediction of the disease course and monitoring of treatment response in patients with LR-MDS. We discuss how next-generation sequencing, increasing knowledge on mechanisms of MDS pathogenesis, and novel therapies may change the current treatment landscape in LR-MDS and why structured assessments of responses, toxicities, and patient-reported outcomes should be incorporated into routine clinical practice.

Interest & Impact

Downloads

7 since deposited on 16 Dec 2022
7 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item